Preparation of the solution for intravenous infusion & method of administration:

**Dose of Solution:**
- **4.5 g IV infusion:** Each Tazopen® vial contains sterile powder Piperacillin Sodium BP equivalent to 4.0 g Piperacillin and Tazobactam Sodium equivalent to 0.5 g Tazobactam.
- **6 g IV infusion:** Each Tazopen® vial contains sterile powder Piperacillin Sodium BP equivalent to 4.5 g Piperacillin and Tazobactam Sodium equivalent to 0.75 g Tazobactam.

**Dosage and Administration:**
- Piperacillin and tazobactam should be administered by intravenous infusion over 30 minutes. The usual total dose of Tazopen® is 4.0 g every six hours for 12 hours if stored at refrigerated temperature (2°C to 8°C) and up to one week in room temperature if stored at refrigerated temperature (2°C to 8°C) and up to 48 hours if stored at room temperature (≤30°C).

**Compatibility:**
- Piperacillin and tazobactam are compatible with sodium bicarbonate, mannitol, dextrose, propylene glycol, sodium chloride, potassium chloride, sodium lactate, sodium acetate, sodium bicarbonate, dextrose, and sodium chloride.
- Piperacillin and tazobactam should be administered as a single intravenous infusion over 30 minutes.

**Pharmacological precaution:**
- If the solution becomes cloudy or contains precipitate,摇匀后再用。
- If the solution is not clear, discard it and prepare a new solution.
- If the solution is not used within the stipulated period, discard it.

**Contraindication:**
- Use of piperacillin and tazobactam in pediatric patients 2 months of age or older with creatinine clearance > 40 mL/min and dialysis patients (hemodialysis and peritoneal dialysis) should be continued in patients from whom Pseudomonas aeruginosa is isolated. If Pseudomonas aeruginosa is isolated in subsequent specimens, piperacillin and tazobactam should not be administered. Piperacillin and tazobactam are contraindicated in patients with a history of anaphylactic/anaphylactoid reactions (including shock) or other serious adverse reactions to piperacillin and tazobactam.

**Adverse reactions:**
- The most common reactions were local infections caused by piperacillin-resistant, beta-lactamase producing strains of *Staphylococcus aureus*. Pseudomonas aeruginosa infections were also reported.

**Interactions with other drugs:**
- Piperacillin and tazobactam are not recommended for use with aminoglycosides, including gentamicin, tobramycin, and amikacin, due to the potential for inactivation of the aminoglycosides.
- Piperacillin and tazobactam should not be used in conjunction with aminoglycosides, including gentamicin, tobramycin, and amikacin, due to the potential for inactivation of the aminoglycosides.

**Special precautions:**
- In patients with renal impairment, the dosage of piperacillin and tazobactam should be reduced accordingly. In patients with severe renal impairment, the dosage of piperacillin and tazobactam should be reduced to 6 g every 12 hours.

**Pregnancy:**
- Tazopen® is not expected to cause harm to the nursing mother or the breastfed infant.

**Pediatric Use:**
- Use of piperacillin and tazobactam in pediatric patients less than 2 months of age has not been established. There are no dosage recommendations for pediatric patients with impaired renal function.